Financings Of The Fortnight: Corporate Venture Is Here To Stay
This article was originally published in The Pink Sheet Daily
Private funding rounds involving corporate venture tend to be much richer in the biotech arena, a recent review indicates.
You may also be interested in...
With Its R&D On Track, GSK R&D Chair Slaoui Cites Individual Responsibility, Culture As Success Factors
The Big Pharma did notably fewer deals in 2011, largely because of stringent criteria, reined in by a tight budget for R&D, but also because of its recent interest in external venture capital partners, some of which are not disclosed to the public.
nContact Surgical Inc. aims to merge the best of surgical and interventional techniques to provide a truly minimally invasive, single procedure solution for atrial fibrillation patients. Its Numeris Coagulation system with VisiTrax is used in the surgical portion of the procedure, in which VisiTrax integrates suction, perfusion and radiofrequency energy to create long linear lesions on the outside of a beating heart. The electrophysiologist then uses a catheter to complete the biatrial lesion pattern inside the heart.
An analysis of corporate venture investment since the beginning of 2008.